Grifols & Talecris Sign Consent Agreement for Merger

Grifols has agreed to the sale of select assets and has entered into certain commercial, lease and manufacturing agreements with the Italian company Kedrion for as many as seven years.

Spanish drugmaker Grifols, S.A. and Talecris Biotherapeutics announced Monday that they have signed a consent agreement with the U.S. Federal Trade Commission (FTC) outlining the conditions for Grifols’ acquisition of Talecris. 

Grifols has agreed to the sale of select assets and has entered into certain commercial, lease and manufacturing agreements with the Italian company Kedrion for as many as seven years.

Kedrion and Grifols will have a contract manufacturing agreement to fractionate and purify Kedrion’s plasma and to deliver IVIG and Albumin under Kedrion’s private label, and Factor VIII under the trade name Koate, for sale in the U.S.